CES Unveiled in Amsterdam Highlights Tech Improving Lives
17.10.2019 19:09:00 EEST | Business Wire | Press release
The Consumer Technology Association (CTA) ® today made several announcements at CES Unveiled in Amsterdam, an official CES® 2020 preview event. Executives, influential media and prominent industry influencers gathered at the record-breaking event to celebrate the latest European innovations and experience what to expect at CES 2020.
CTA announced that eight companies from the Netherlands and the surrounding region were announced as CES 2020 Innovation Honorees. Best of Innovation honorees include Dutch company Hydraloop Systems BV in the Sustainability, Eco-Design & Smart Energy category and British company Valerann in the Smart Cities category.
“Europe is a hotbed for innovation consistently driving our industry forward and we saw the promise and power of technology at CES Unveiled in Amsterdam,” said Karen Chupka, EVP, CES. “CES 2020 will showcase the most innovative tech from Europe that truly has the potential to make people’s lives better.”
The remaining honorees will be revealed at CES Unveiled in Paris on Oct. 22., 2019, and CES Unveiled New York on Nov. 7, 2019. Honorees will be posted online at CES.tech starting Nov. 7, 2019 and many will showcase their winning products at CES 2020, Jan. 7-10, in Las Vegas.
In its third year, CES Unveiled in Amsterdam set records by selling out exhibit space and bringing together more than 1,500 attendees from nearly 50 countries. The event also featured government and industry leaders from the Netherlands and surrounding regions including, Pete Hoekstra, U.S. Ambassador to the Netherlands; Mona Keijzer, Netherlands State Secretary for Economic Affairs and Climate Policy; Femke Halsema, Mayor of Amsterdam; and Corinne Vigreux, co-founder of TomTom and founder of CODAM.
Europe welcomed more than 16,000 attendees to CES 2019 and continues to lead innovation by example. The European Union had a strong presence at CES Unveiled in Amsterdam, featuring leaders including, Katerina Borunska, Policy Officer, European Commission; Hubert Cottogni, Director, Head of Mandate Management, European Investment Fund; and Els Sweeney-Bindels, Head of EIB Amsterdam Office, European Investment Bank. CES Unveiled promotes the continued value it shares with Europe through partnerships across government, business and research.
TechLeap.NL also announced their new visual identity and the 50 startups they are bringing to CES 2020 as part of Eureka Park. HRH Prince Constantijn van Oranje, Special Envoy at TechLeap.NL, also discussed why CES is important for Dutch startups and why he is working to make the Netherlands the best place for tomorrow’s leaders in technology.
Owned and produced by CTA, CES 2020, the world’s largest and most influential tech event, will run Jan. 7-10, 2020, in Las Vegas, NV and provide access to the most transformative tech across various marketplaces, such as 5G connectivity, artificial intelligence, augmented and virtual reality, smart home, smart cities, vehicles, digital health and more. Industry leaders and rising stars will come together again to pioneer future innovation driving the ever-evolving tech industry.
Registration for CES 2020 is now open. For the latest exhibitor news and show announcements, visit CES.tech.
About CES:
CES® is the largest, most influential tech event in the world – the proving ground for breakthrough technologies and global innovators. This is where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. Owned and produced by the Consumer Technology Association (CTA)®, CES features every aspect of the tech sector. Learn more at CES.tech and follow CES on social.
About Consumer Technology Association:
As North America’s largest technology trade association, CTA® is the tech sector. Our members are the world’s leading innovators – from startups to global brands – helping support more than 18 million American jobs. CTA owns and produces CES® – the largest, most influential tech event on the planet. Find us at CTA.tech. Follow us @CTAtech.
UPCOMING EVENTS
-
CES Unveiled in Paris
October 22 – Paris, France -
Consumer Technology Hall of Fame
November 6, 2019 – New York, NY -
CES Unveiled New York
November 7 – New York, NY -
CES Unveiled Las Vegas
January 5, 2020 – Las Vegas, NV -
CES 2020
January 7-10, 2020 – Las Vegas, NV
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005692/en/
Contact information
Justin Siraj
703-907-7415
jsiraj@CTA.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom